Aging, Dynapenia, Physical Impairment
Conditions
Keywords
exercise, protein, muscle function, aging
Brief summary
Investigate the effect of 12 weeks mixed power training (power and functional exercises) combined with a protein supplementation (30g/d) or not (placebo) on physiological characteristics of muscle and functional capacities in elderly men.
Detailed description
Life habits are know to be able to prevent the loss of functional capacities and muscle function during aging process. More specifically, protein intake is important to maintain muscle function in older adults. Another non pharmacological intervention and well recognized for its efficacy, it's exercise training. Recently, it has been observed than muscle quality is more important to maintain physical autonomy than muscle mass per se. In addition, muscle quality is more related to functional capacities than muscle mass. Due to this recent finding, it has been proposed that muscle power training would be the best exercise intervention to prevent the loss of mobility.
Interventions
OTHERExercise + Placebo group
1/2 of the subject will follow a mixed power training: 4 power exercises + 6 functional exercises combined to a placebo
OTHERExercise + Protein group
1/2 of the subject will receive 30 g/ d of protein (leucine+ vitD; divided in three equal doses: morning, afternoon and evening) + will follow a mixed power training: 4 power exercises + 6 functional exercises.
Sponsors
Université du Québec a Montréal
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
MALE
Age
60 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Elderly men * 60 years and older * Sedentary men * Not obese (BMI \<30 kg/m2) * Living in free-living community
Exclusion criteria
* Not able to follow an exercise program (doctor authorization: XAAP) * Having Lactose intolerance * Having Pace marker * Having Metabolism disorder * No weight stable since the last 6 months * No stable medication (same dose and type since at least 6 months)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in walking speed | Change from Baseline walking speed at 12 weeks measure in all subjects | evaluate using the 4m- normal walking speed (m/sec) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in lower limb muscle quality | Change from Baseline lower limb muscle quality at 12 weeks measure in all subjects | Knee extension muscle strength (isometric (N)/ lower limb muscle mass (kg)) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Change in mitochondrial activity | Change from Baseline mitochondrial activity at 12 weeks measure in half of the subjects | citrate synthase activity (unit: percent) |
Outcome results
None listed